No products in the cart.
Rabbit Polyclonal Phospho-JIP-1 (T103) antibody (STJ90715)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, IHC, IF, ELISA
Recommended dilution: WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:5000;
Recommended protocols: check protocols
Click or hover above images to see image description for JIP-1 (phospho Thr103) Polyclonal Antibody.
Check alternative names for the antibodyExpand
MAPK8IP1 antibody, IB1 antibody, JIP1 antibody, PRKM8IP antibody,|C jun amino terminal kinase interacting protein 1 antibody|C-jun-amino-terminal kinase-interacting protein 1 antibody|IB 1 antibody|IB-1 antibody|IB1 antibody|Islet brain 1 antibody|Islet-brain 1 antibody|JIP 1 antibody|JIP-1 antibody|JIP1_HUMAN antibody|JNK interacting protein 1 antibody|JNK MAP kinase scaffold protein 1 antibody|JNK-interacting protein 1 antibody|MAPK8IP 1 antibody|MAPK8IP1 antibody|MAPK8IP1 mitogen-activated protein kinase 8 interacting protein 1 antibody|Mitogen activated protein kinase 8 interacting protein 1 antibody|Mitogen-activated protein kinase 8-interacting protein 1 antibody|PRKM8 antibody|PRKM8 interacting protein antibody|PRKM8IP antibody|Anti-JIP1 antibody (ab24449)
SCBT cat No: sc-135957|
JIP-1 (phospho Thr103) Polyclonal Antibody
|Catalogue No.|| |
Human, Mouse, Rat
Phospho-JIP-1 (T103) Polyclonal Antibody detects endogenous levels of JIP-1 protein only when phosphorylated at T103.
Synthesized phospho-peptide derived from JIP-1 (phospho Thr103) at AA range 40-120
WB, IHC, IF, ELISA
|Recommended dilution|| |
WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:5000;
|Molecular weight|| |
JIP-1 (phospho Thr103) Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
JIP-1 (phospho Thr103) Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
C-Jun-amino-terminal kinase-interacting protein 1 antibody, JIP-1 antibody, JNK-interacting protein 1 antibody, Islet-brain 1 antibody, IB-1 antibody, JNK MAP kinase scaffold protein 1 antibody, Mitogen-activated protein kinase 8-interacting protein 1 antibody
|Protein names|| |
C-Jun-amino-terminal kinase-interacting protein 1 , JIP-1 , JNK-interacting protein 1 , Islet-brain 1 , IB-1 , JNK MAP kinase scaffold protein 1 , Mitogen-activated protein kinase 8-interacting protein 1
|Protein function|| |
The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module. Required for JNK activation in response to excitotoxic stress. Cytoplasmic MAPK8IP1 causes inhibition of JNK-regulated activity by retaining JNK in the cytoplasm and inhibiting JNK phosphorylation of c-Jun. May also participate in ApoER2-specific reelin signaling. Directly, or indirectly, regulates GLUT2 gene expression and beta-cell function. Appears to have a role in cell signaling in mature and developing nerve terminals. May function as a regulator of vesicle transport, through interactions with the JNK-signaling components and motor proteins (By similarity). Functions as an anti-apoptotic protein and whose level seems to influence the beta-cell death or survival response.
|Protein tissue specificity|| |
Highly expressed in brain. Expressed in neurons, localizing to neurite tips in differentiating cells. Also expressed in the pancreas, testis and prostate. Low levels in heart, ovary and small intestine. Decreased levels in pancreatic beta cells sensitize cells to IL-1-beta-induced apoptosis.
|Involvement in disease|| |
Diabetes mellitus, non-insulin-dependent (NIDDM) [MIM:125853]: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body’s own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. . Note: The disease may be caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
The destruction boxes (D-box) may act as recognition signals for degradation via the ubiquitin-proteasome pathway. / A minimal inhibitory domain prevents pancreatic beta cell apoptosis in vitro, and prevents activation of c-jun by MAPK8, MAPK9 and MAPK10. / The SH3 domain mediates homodimerization. / Belongs to the JIP scaffold family. / Contains 1 PID domain. / Contains 1 SH3 domain.
|Protein post-translational modifications|| |
Phosphorylated by MAPK8, MAPK9 and MAPK10. Phosphorylation on Thr-103 is also necessary for the dissociation and activation of MAP3K12. Phosphorylated by isoform 1 and isoform 2 of VRK2. Hyperphosphorylated during mitosis following activation of stress-activated and MAP kinases. / Ubiquitinated. Two preliminary events are required to prime for ubiquitination; phosphorylation and an increased in intracellular calcium concentration. Then, the calcium influx initiates ubiquitination and degradation by the ubiquitin-proteasome pathway.
|Protein cellular localization|| |
Cytoplasm / Cytoplasm > perinuclear region / Nucleus / Endoplasmic reticulum membrane / Mitochondrion membrane
AntibodyPlus can customize JIP-1 (phospho Thr103) Antibody according to your requirement, including bulk product size,etc. Please contact firstname.lastname@example.org. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: